Overview
The present invention relates to peptide modified with one or more non-coded amino acid preferably dehydrophenylalanine incorporated at strategic positions for increasing glucose stimulated insulin secretion and regulating blood glucose levels. The incorporation of dehydrophenylalanine at strategic positions in the peptide confers enhanced resistance to enzymatic degradation, which leads to an increased half-life in vivo. The novel dehydrophenylalanine containing peptide of the present invention can be employed for the development of a novel drug or pharmaceutical composition for Type 2 diabetes.